Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Importance of Personalized Medicine in Urological Cancers Publisher



Khatami F1 ; Nikfar S2 ; Gholami K1 ; Navard FG1 ; Hasanzad M3 ; Tamehrizadeh SS1 ; Karimaei S1 ; Rezaeian AR4 ; Mirzaei A1 ; Feyzabadi A1 ; Aghamir SMK1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Personalized Medicine Research Center (PMRC), The Endocrinology and Metabolism Research Institute (EMRI), Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Koomesh Published:2022


Abstract

Introduction: Personalized medicine (PM) refers to a set of medical, diagnostic, and therapeutic activities and approaches based on the specific characteristics of each patient chr ('39')s genome. In fact, individual-centered medical approaches are based on personalization, meaning that each person chr ('39')s gene sequence and polymorphisms (SNPs) are different and explain the different courses of urological cancers and the different efficiencies of individuals in a protocol. The treatment is constant. Based on data from the Human Genome and Gene Sequence Project, along with proteomics, metabolomics, and transcriptomics information, a number of molecular biomarkers are suggested as potential targets for guided cancer therapies. In urological malignancies, the expression and clinical significance of carbonic anhydrase in type IX in the bladder, kidney, and urinary tract cancers and the primary therapeutic approaches have been discussed. Prostate membrane antigen and radiolabeled analog neuropeptide receptors for prostate cancer are considered valuable prognostic factors in clinical trials. The results of the treatment of patients with urological cancers from a person-centered medical perspective will impose a lower cost on the patient and more effective treatment, which we will discuss in this article. © 2022, Semnan University of Medical Sciences. All rights reserved.